Nature Communications (Apr 2020)

Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition

  • Jenny H. Lee,
  • Elena Shklovskaya,
  • Su Yin Lim,
  • Matteo S. Carlino,
  • Alexander M. Menzies,
  • Ashleigh Stewart,
  • Bernadette Pedersen,
  • Malama Irvine,
  • Sara Alavi,
  • Jean Y. H. Yang,
  • Dario Strbenac,
  • Robyn P. M. Saw,
  • John F. Thompson,
  • James S. Wilmott,
  • Richard A. Scolyer,
  • Georgina V. Long,
  • Richard F. Kefford,
  • Helen Rizos

DOI
https://doi.org/10.1038/s41467-020-15726-7
Journal volume & issue
Vol. 11, no. 1
pp. 1 – 12

Abstract

Read online

A significant proportion of patients develop innate or acquired resistance to immune checkpoint inhibitors. Here, the authors show that resistance to anti-PD-1 blockade is associated with TGF-beta driven major histocompatibility complex I (MHCI) down-regulation and a de-differentiated phenotype in melanoma patients.